Comparative study of the safety profile and overall health cost of the rituximab-chop therapy versus bendamustine-rituximab in patients with non-hodgkin lymphoma

• Autores: Rodrigo Bonilla Peñarrubia, Paola Beneit Villena, A. Soria Aledo, A Ramón Albert, Carlos Devesa García, Tamara García Pérez, Pedro García Salom
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 17, Nº. 5, 2015, pág. 3
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective: Study of the safety profile and the overall health care impact of the rituximab-bendamustine therapy (R-B) versus rituximab-CHOP (R-CHOP) in our health care setting.

    Method: A six months retrospective follow-up was carried out on patients treated with each of the schedules. To assess the safety profile 􀀏 we determined data of hematologic and non-hematologic adverse reactions􀀏 and estimated the overall health care cost of each schedule during the six months of follow-up.

    Results: The R-B group underwent a lower number of hematologic adverse reactions􀀏 mainly leukopenia RCHOPR = 0.6􀀙2,􀀏 RRB = 0.17􀀏, (p = 0.0􀀗41) and neutropenia RCHOPR = 0.6􀀙2,􀀏 RRB = 0.33,􀀏 (p = 0.18􀀛) resulting in lower number of visits to the emergency service 1.5 visits vs. 1.9􀀜 visits in the R-CHOP group􀀏 lower number of hospital stay 2.17 days in the R-B group vs. 6􀀙.9􀀜 days in the R-CHOP group􀀏 and thus lower sum of costs derived from the therapy. However the overall health care cost was slightly higher than with R-CHOP (R-B: €15,9􀀏􀀜63􀀙.5 vs. €14,699􀀗􀀏􀀙􀀜􀀜 R-CHOP).

    Conclusions: The R-B schedule is a good option for the treatment of NHL since it has confirmed similar efficacy and lower rate of adverse effects than R-CHOP􀀏 likewise􀀏 it has been established that the overall health care cost is similar in both schedules􀀏 which is a good alternative to R-CHOP for the treatment of the NHL.